Table 3 Impact of prognostic factors on recurrence-free survival (RFS) (N = 144)
Covariates | No. of patients | 5-year RFS | Median RFS | Univariate analysis p value | Multivariate analysis H.R. (95% C.I.) p value |
|---|---|---|---|---|---|
Age | |||||
≤ 45 years | 76 | 58% | 87 months | 0.17 | |
> 45 years | 68 | 44% | 39 months | ||
Grade | |||||
Low | 108 | 59% | 87 months | 0.04 | 2.2 (1.17–4.16) |
High | 24 | 32% | 20 months | 0.01 | |
PNI | |||||
Absent | 82 | 58% | 76 months | 0.06 | 1.90 (1.11–3.4) |
Present | 41 | 43% | 24 months | 0.01 | |
ECE | |||||
Absent | 102 | 58% | 41 months | 0.06 | |
Present | 33 | 37% | 17 months | ||
DOI | |||||
≤ 10 mm | 69 | 57% | 70 months | 0.32 | |
> 10 mm | 57 | 47% | 35 months | ||
Node metastasis pN) | |||||
Negative (pN-ve) | 69 | 56% | Not reached | 0.03 | 1.53 (0.88–2.67) |
Positive (pN+ve) | 72 | 40% | 38 months | 0.13 | |
Stage (AJCC 7th) | |||||
Early | 47 | 65% | Not reached | 0.11 | 1.3 (0.55–3.06) |
Advanced | 95 | 46% | 45 months | 0.55 |